Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.19-
QQQ
709.440.03%
BTC/USD
77009.950.4943%
DIA
530.60-
GLD
402.250.13%
TLT
81.930.02%

Intensity Therapeutics Inc

INTSNASDAQ
Trade with Public
Trade with Public
$4.00
-0.07-1.72%
At close: Sep 2, 5:00 PM EST
$4.22
0.225.5%
After Hours: Sep 1, 9:08 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

Intensity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Intensity Therapeutics (INTS).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$4Upside to Avg. PT+1.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026HC Wainwright & Co.Swayampakula RamakanthPT RaiseBuy$5→$7
Aug 20, 2025BenchmarkRobert WassermanPT CutSpeculative Buy$4→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Intensity Therapeutics (NASDAQ:INTS) with a Buy and raises the price target from $5 to $7.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $1.5

Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $4 to $1.5.
Benzinga Newsdesk

PRO
Brookline Capital Upgrades Intensity Therapeutics to Buy, Announces $3 Price Target

Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 price target.
Benzinga Newsdesk

PRO
Alliance Global Partners Initiates Coverage On Intensity Therapeutics with Buy Rating, Announces Price Target of $8.5

Alliance Global Partners analyst James Molloy initiates coverage on Intensity Therapeutics (NASDAQ:INTS) with a Buy rating and announces Price Target of $8.5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Intensity Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Intensity Therapeutics (NASDAQ:INTS) with a Buy and maintains $5 price target.
Benzinga Newsdesk

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved